STRATEGIC SALES & MARKETING AGREEMENTStrategic Sales & Marketing Agreement • April 17th, 2017 • Imprimis Pharmaceuticals, Inc. • Pharmaceutical preparations • California
THIS STRATEGIC SALES & MARKETING AGREEMENT (the “Agreement”) is effective as of the last date provided for on the signature page and is entered into by and between Cameron Ehlen Group, Inc., a Minnesota corporation doing business as Precision Lens, having its principal place of business at 5715 W. Old Shakopee Road, Suite 150, Bloomington, MN 55437 (“Precision Lens”) and Imprimis Pharmaceuticals, Inc., a Delaware corporation, and its subsidiaries, having its principal place of business at 12264 El Camino Real, Suite 350, San Diego, CA 92130 (“Imprimis”).
Imprimis Pharmaceuticals and Precision Lens Sign Agreement to Expand Imprimis’ Ophthalmic Portfolio Market Opportunity in the U.S. Midwest Largest distributor of ophthalmic products in the Midwest to expand Imprimis’ ability to serve strategic...Sales Representation Agreement • April 17th, 2017 • Imprimis Pharmaceuticals, Inc. • Pharmaceutical preparations
San Diego, Calif. and Bloomington, Minn. – April 18, 2017 — Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) (“Imprimis”), an ophthalmology-focused pharmaceutical company, and Cameron Ehlen Group, d/b/a Precision Lens (“Precision Lens”), today announced the signing of a three-year exclusive sales representation agreement. Under the agreement, Precision Lens will deploy a dedicated sales team to introduce Imprimis’ ophthalmic portfolio into select geographies in the U.S., primarily focused in 13 states in the U.S. Midwest. Precision Lens, which sells and distributes more than 60 percent of the intraocular lens (IOLs) for cataract surgery in its markets, will add resources to exclusively sell Imprimis’ pharmaceutical products, including Dropless Therapy®, LessDrops® combination eye drops, Simple Drops™ preservative-free glaucoma drops, MKO Melt™ conscious sedation, and medications typically used for dilation, general inflammation and infection. Imprimis will continue to focus its sales effo
